Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLMNASDAQ:CGTXNASDAQ:CYTHNASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$5.52-3.1%$6.16$4.47▼$35.98$6.28M0.999,510 shs4,900 shsCGTXCognition Therapeutics$0.26+1.8%$0.33$0.22▼$2.54$15.81M0.752.73 million shs932,185 shsCYTHCyclo Therapeutics$0.72$0.72$0.55▼$1.45$23.72M-0.57524,757 shsN/APASGPassage Bio$0.33-14.4%$0.37$0.26▼$1.33$24.30M1.71362,121 shs402,992 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics0.00%-11.49%-19.49%-40.00%-72.14%CGTXCognition Therapeutics0.00%-14.52%-14.11%-47.94%-86.58%CYTHCyclo Therapeutics0.00%0.00%0.00%+1.39%-44.57%PASGPassage Bio0.00%0.00%+5.68%-21.78%-57.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLMApollomicsN/AN/AN/AN/AN/AN/AN/AN/ACGTXCognition Therapeutics3.0682 of 5 stars3.55.00.00.00.61.71.3CYTHCyclo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APASGPassage Bio2.0378 of 5 stars3.52.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 0.00N/AN/AN/ACGTXCognition Therapeutics 3.00Buy$5.632,067.63% UpsideCYTHCyclo Therapeutics 2.33Hold$0.9531.83% UpsidePASGPassage Bio 3.00Buy$7.502,140.14% UpsideCurrent Analyst Ratings BreakdownLatest APLM, CGTX, PASG, and CYTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/24/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$1.49M4.08N/AN/A$4.48 per share1.23CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ACYTHCyclo Therapeutics$870.73K27.24N/AN/A$0.21 per share3.43PASGPassage BioN/AN/AN/AN/A$0.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$53.86MN/A0.00∞N/AN/AN/AN/AN/ACGTXCognition Therapeutics-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)CYTHCyclo Therapeutics-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/APASGPassage Bio-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)Latest APLM, CGTX, PASG, and CYTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/A5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACYTHCyclo TherapeuticsN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A1.391.39CGTXCognition TherapeuticsN/A2.092.09CYTHCyclo TherapeuticsN/A0.170.16PASGPassage BioN/A3.743.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%CGTXCognition Therapeutics43.35%CYTHCyclo Therapeutics68.55%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/ACGTXCognition Therapeutics14.40%CYTHCyclo Therapeutics29.78%PASGPassage Bio4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics451.10 millionN/ANot OptionableCGTXCognition Therapeutics2061.99 million53.07 millionNot OptionableCYTHCyclo Therapeutics932.92 million23.12 millionNo DataPASGPassage Bio13062.15 million59.48 millionOptionableAPLM, CGTX, PASG, and CYTH HeadlinesRecent News About These CompaniesPassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program UpdateJune 23 at 7:00 AM | globenewswire.comPassage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy DevelopmentMay 17, 2025 | msn.comPassage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestreMay 13, 2025 | zonebourse.comPASSAGE BIO, INC. : Wedbush persiste à l'achatMay 13, 2025 | zonebourse.comPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsMay 13, 2025 | globenewswire.comInsider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of StockApril 25, 2025 | insidertrades.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 SharesApril 18, 2025 | insidertrades.comOrbiMed Advisors vend des actions de Passage Bio pour 49.704$April 18, 2025 | fr.investing.comL’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marchéApril 8, 2025 | fr.investing.comL’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$March 31, 2025 | fr.investing.comL'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$March 14, 2025 | fr.investing.comPassage Bio (PASG) Upgraded to Buy: Here's What You Should KnowMarch 7, 2025 | zacks.comPASSAGE BIO, INC. : Chardan Research reste à l'achatMarch 5, 2025 | zonebourse.comL’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$March 5, 2025 | fr.investing.comPassage Bio price target lowered to $6 from $7 at ChardanMarch 5, 2025 | markets.businessinsider.comPassage Bio publie ses résultats du quatrième trimestre et de l'année 2024.March 4, 2025 | zonebourse.comPassage Bio reports FY24 EPS ($1.07) vs ($1.86) last yearMarch 4, 2025 | markets.businessinsider.comPassage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business HighlightsMarch 4, 2025 | globenewswire.comPassage Bio to Participate in Upcoming Investor ConferencesFebruary 26, 2025 | globenewswire.comPassage Bio will again trim workforce in latest cost-cutting moveFebruary 16, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLM, CGTX, PASG, and CYTH Company DescriptionsApollomics NASDAQ:APLM$5.52 -0.18 (-3.09%) Closing price 03:55 PM EasternExtended Trading$5.48 -0.05 (-0.89%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Cognition Therapeutics NASDAQ:CGTX$0.26 +0.00 (+1.76%) Closing price 04:00 PM EasternExtended Trading$0.27 +0.01 (+5.20%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Cyclo Therapeutics NASDAQ:CYTH$0.72 0.00 (0.00%) As of 03/26/2025Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Passage Bio NASDAQ:PASG$0.33 -0.06 (-14.37%) Closing price 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.66%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
